{
  "id": "mhgap#risk_safety_bdf41160",
  "content": "opioid use at their usual dose after withdrawal that they are at an increased risk of »\nClonidine or Lofexidine: If opioid substitution medications are not available, clonidine or\noverdosing. Due to these risks, withdrawal is best undertaken when there is a plan for\nlofexidine can be used to manage some opioid withdrawal symptoms, namely hyperarousal.\nadmission to a residential rehabilitation or other psychosocial support programme.\nThey are given at dose ranges of 0.1-0.15 mg 3 times daily p.o. and are dosed according to\nAlternatively, the person may be considered for opioid substitution therapy with either\nbody weight. Light-headedness and sedation may result. Monitor blood pressure closely.\nmethadone or buprenorphine; see the opioid agonist maintenance treatment section (see\nOther symptoms of withdrawal should also be treated, i.e. nausea with anti-emetics, pain\nprotocol 5), and select one of the following pharmacological options for management:\nwith simple analgesics, and insomnia with light sedatives.\n»\nBuprenorphine: Buprenorphine is given sublingually at a dose range of 4-16 mg per day »\nMorphine sulphate: 10-20 mg as an initial dose with 10 mg extra dose if needed.\nfor 3-14 days for withdrawal management. Before initiating buprenorphine treatment, it is",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "sleep",
      "risk_safety",
      "screening_cues",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety opioid use at their usual dose after withdrawal that they are at an increased risk of »\nClonidine or Lofexidine: If opioid substitution medications are not available, clonidine or\noverdosing. Due to these risks, withdrawal is best undertaken when there is a plan for\nlofexidine can be used to manage some opioid withdrawal symptoms, namely hyperarousal.\nadmission to a residential rehabilitation or other psychosocial support programme.\nThey are given at dose ranges of 0.1-0.15 mg 3 times daily p.o. and are dosed according to\nAlternatively, the person may be considered for opioid substitution therapy with either\nbody weight. Light-headedness and sedation may result. Monitor blood pressure closely.\nmethadone or buprenorphine; see the opioid agonist maintenance treatment section (see\nOther symptoms of withdrawal should also be treated, i.e. nausea with anti-emetics, pain\nprotocol 5), and select one of the following pharmacological options for management:\nwith simple analgesics, and insomnia with light sedatives.\n»\nBuprenorphine: Buprenorphine is given sublingually at a dose range of 4-16 mg per day »\nMorphine sulphate: 10-20 mg as an initial dose with 10 mg extra dose if needed.\nfor 3-14 days for withdrawal management. Before initiating buprenorphine treatment, it is Opioid use at their usual dose after withdrawal that they are at an increased nguy cơ of »\nclonidine or lofexidine: if opioid substitution medications are not available, clonidine or\noverdosing. due to these risks, withd..."
}